Gustav Christensen was named President and Chief Executive Officer January 1, 2009. He first joined Dyax as our Executive Vice President and Chief Business Officer in April 2007 and oversaw the Company's partnering strategy as well as other business development activities such as licensing and collaboration transactions.
Previously, Mr. Christensen was Managing Director of Apeiron Partners, LLC, a boutique life sciences investment bank, from 2005 to 2007. He began his career as General Manager at Baxter Travenol Laboratories and left in 1983 to become the Vice President of Business Development at Genetics Institute Inc. from 1983 to 1988. Additionally, he has been the CEO or senior manager of several biopharmaceutical firms. Mr. Christensen received his Master of Science in Economics from the University of Aarhus (Denmark) and his Master of Business Administration from Harvard Business School.
George Migausky joined Dyax as Executive Vice President and Chief Financial Officer in August 2008. He brings over 20 years of experience serving as Chief Financial Officer for various life science and biotechnology companies. Prior to Dyax, Mr. Migausky served as CFO of Wellstat Management Company, a privately-held company responsible for the strategy, business development and operations of an affiliated group of five life science companies.
From 1990 to 2004, he served as CFO at IGEN International where he was instrumental in preparing the company for its initial public offering in 1994, its merger with F. Hoffman La Roche in 2004 and the simultaneous spinoff of BioVeris Corporation as an independent public company. He served as CFO of BioVeris through to 2007. George Migausky is a Certified Public Accountant and received an M.B.A. from Babson College and a B.S. from Boston College.
Dr. Burt Adelman joined Dyax as Chief Medical Officer in February 2012 and brings with him over twenty years of experience and expertise in drug development and commercialization. He began his career with Biogen Idec (then Biogen) in 1991 as Director of Medical Research, and held positions of increasing responsibility before retiring as Executive Vice President of Portfolio Strategy in 2007. At Biogen, he led the successful development and regulatory efforts for a number of important biologic therapeutics including: Angiomax®, Avonex®, Amevive® and Tysabri®. Prior to joining Dyax, Dr. Adelman was interim President of Research and Development at Eleven Biotherapeutics.
Dr. Adelman serves as a lecturer in medicine at the Harvard Medical School. He received his M.D. from Cornell Medical College.